Lista de obras -

5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study

artículo científico publicado en 2018

Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas

artículo científico publicado en 2015

An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer

artículo científico publicado en 2018

Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series

scientific article published on 26 October 2012

Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience.

artículo científico publicado en 2013

Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas.

artículo científico publicado en 2012

Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases.

artículo científico publicado en 2016

Efficacy of buparlisib in treating breast cancer.

artículo científico publicado en 2017

Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer

artículo científico publicado en 2017

Emerging PARP inhibitors for treating breast cancer

artículo científico publicado en 2018

Emotional distress and subjective impact of the disease in young women with breast cancer and their spouses

artículo científico publicado en 2017

Eribulin mesylate for the treatment of late-stage breast cancer.

artículo científico publicado en 2011

Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.

artículo científico publicado en 2017

Intraperitoneal chemotherapy in the treatment of advanced ovarian cancer

artículo científico publicado en 2010

KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer

artículo científico publicado en 2016

LTBK-04 FIRST RESULTS OF THE RANDOMIZED PHASE II STUDY ON DEPATUX –M ALONE, DEPATUX-M IN COMBINATION WITH TEMOZOLOMIDE AND EITHER TEMOZOLOMIDE OR LOMUSTINE IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA: FIRST REPORT FROM INTELLANCE 2/EORTC TRIAL 1410

artículo científico publicado en 2017

Lapatinib in metastatic breast cancer.

artículo científico publicado en 2009

Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer

artículo científico publicado en 2018

Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations

artículo científico publicado en 2014

NY-ESO-1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartment.

artículo científico publicado en 2011

Olaparib for the treatment of breast cancer.

artículo científico publicado en 2017

Optimizing the Retrieval of the Vital Status of Cancer Patients for Health Data Warehouses by Using Open Government Data in France

artículo científico publicado en 2022

P20.01 MEVITEM: A European, randomized, open-label Phase I/II study of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent or refractory medulloblastoma presenting an activation of the Sonic Hedgeho

artículo científico publicado en 2016

Patient-centered simulations to assess the usefulness of the 70-gene signature for adjuvant chemotherapy administration in early-stage breast cancer

artículo científico publicado en 2019

Pertuzumab for the treatment of breast cancer

scientific article published on 29 August 2019

Pharmacokinetic drug evaluation of abemaciclib for advanced breast cancer

scientific article published on 05 January 2019

Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).

artículo científico publicado en 2016

Prognostic and predictive factors for gliomas in adults

artículo científico publicado en 2009

Prognostic factors for patients treated for a recurrent FIGO stage III ovarian cancer: A retrospective study of 108 cases

artículo científico publicado en 2011

Pulse oximetry and high-dose vasopressors: a comparison between forehead reflectance and finger transmission sensors.

artículo científico publicado en 2012

QLIF-47. HEALTH RELATED QUALITY OF LIFE AND NEUROLOGICAL DETERIORATION FREE SURVIVAL IN INTELLANCE 2/EORTC TRIAL 1410, A RANDOMIZED PHASE II STUDY ON ABT414 IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA

SNP array analysis reveals novel genomic abnormalities including copy neutral loss of heterozygosity in anaplastic oligodendrogliomas

artículo científico publicado en 2012

Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.

artículo científico publicado en 2017

Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration

artículo científico publicado en 2015

Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer

artículo científico publicado en 2020

The self-reported perceptions of the repercussions of the disease and its treatments on daily life for young women with breast cancer and their partners

scientific article published on 08 October 2018

Tumor clone dynamics in lethal prostate cancer

artículo científico publicado en 2014

Vinflunine for the treatment of breast cancer

artículo científico publicado en 2016

What is the best choice of partner chemotherapy with trastuzumab for metastatic breast cancer?

artículo científico publicado en 2012

[The role of interval surgery in the treatment's strategy of advanced ovarian cancer]

artículo científico publicado en 2011

[Trastuzumab emtansine in the systemic treatment of HER-2-positive breast cancer brain metastases].

artículo científico publicado en 2016

[Tumor resistance to HER2 inhibitors: the drug sedimentation concept].

artículo científico publicado en 2012

[Unusual antenatal gestational choriocarcinoma]

artículo científico publicado en 2014

bc-GenExMiner 3.0: new mining module computes breast cancer gene expression correlation analyses

artículo científico publicado en 2013

miR-370-3p Is a Therapeutic Tool in Anti-glioblastoma Therapy but Is Not an Intratumoral or Cell-free Circulating Biomarker

scientific article published on 13 September 2018

Lista de obras de

5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study

Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas

An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer

Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series

Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience.

Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas.

Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases.

Efficacy of buparlisib in treating breast cancer.

Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer

Emerging PARP inhibitors for treating breast cancer

Emotional distress and subjective impact of the disease in young women with breast cancer and their spouses

Eribulin mesylate for the treatment of late-stage breast cancer.

Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.

Intraperitoneal chemotherapy in the treatment of advanced ovarian cancer

KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer

LTBK-04 FIRST RESULTS OF THE RANDOMIZED PHASE II STUDY ON DEPATUX –M ALONE, DEPATUX-M IN COMBINATION WITH TEMOZOLOMIDE AND EITHER TEMOZOLOMIDE OR LOMUSTINE IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA: FIRST REPORT FROM INTELLANCE 2/EORTC TRIAL 1410

Lapatinib in metastatic breast cancer.

Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer

Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations

NY-ESO-1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartment.

Olaparib for the treatment of breast cancer.

Optimizing the Retrieval of the Vital Status of Cancer Patients for Health Data Warehouses by Using Open Government Data in France

P20.01 MEVITEM: A European, randomized, open-label Phase I/II study of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent or refractory medulloblastoma presenting an activation of the Sonic Hedgeho

Patient-centered simulations to assess the usefulness of the 70-gene signature for adjuvant chemotherapy administration in early-stage breast cancer

Pertuzumab for the treatment of breast cancer

Pharmacokinetic drug evaluation of abemaciclib for advanced breast cancer

Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).

Prognostic and predictive factors for gliomas in adults

Prognostic factors for patients treated for a recurrent FIGO stage III ovarian cancer: A retrospective study of 108 cases

Pulse oximetry and high-dose vasopressors: a comparison between forehead reflectance and finger transmission sensors.

QLIF-47. HEALTH RELATED QUALITY OF LIFE AND NEUROLOGICAL DETERIORATION FREE SURVIVAL IN INTELLANCE 2/EORTC TRIAL 1410, A RANDOMIZED PHASE II STUDY ON ABT414 IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA

SNP array analysis reveals novel genomic abnormalities including copy neutral loss of heterozygosity in anaplastic oligodendrogliomas

Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.

Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration

Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer

The self-reported perceptions of the repercussions of the disease and its treatments on daily life for young women with breast cancer and their partners

Tumor clone dynamics in lethal prostate cancer

Vinflunine for the treatment of breast cancer

What is the best choice of partner chemotherapy with trastuzumab for metastatic breast cancer?

[The role of interval surgery in the treatment's strategy of advanced ovarian cancer]

[Trastuzumab emtansine in the systemic treatment of HER-2-positive breast cancer brain metastases].

[Tumor resistance to HER2 inhibitors: the drug sedimentation concept].

[Unusual antenatal gestational choriocarcinoma]

bc-GenExMiner 3.0: new mining module computes breast cancer gene expression correlation analyses

miR-370-3p Is a Therapeutic Tool in Anti-glioblastoma Therapy but Is Not an Intratumoral or Cell-free Circulating Biomarker